The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Scott P. Henry

ISIS Pharmaceuticals

Carlsbad

CA 92010

United States

[email]@isisph.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • ISIS Pharmaceuticals, Carlsbad, CA 92010, United States. 2000 - 2012
  • Department of Toxicology, Isis Pharmaceuticals Inc., Carlsbad, CA 92008, USA. 1997 - 2004
  • ISIS Pharmaceuticals, Carlsbad Research Center, 2292 Faraday Avenue, Carlsbad, USA. 2002
  • Toxicology and Pharmacokinetics Department, Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, USA. 2002

References

  1. Renal uptake and tolerability of a 2'-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey. Henry, S.P., Johnson, M., Zanardi, T.A., Fey, R., Auyeung, D., Lappin, P.B., Levin, A.A. Toxicology (2012) [Pubmed]
  2. Assessment of the effects of ISIS 2302, an anti-sense inhibitor of human ICAM-1, on cellular and humoral immunity in mice. Henry, S.P., Levin, A.A., White, K., Mennear, J.H. J. Immunotoxicol (2006) [Pubmed]
  3. Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides. Henry, S.P., Marcusson, E.G., Vincent, T.M., Dean, N.M. Trends Pharmacol. Sci. (2004) [Pubmed]
  4. Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice. Henry, S.P., Denny, K.H., Templin, M.V., Yu, R.Z., Levin, A.A. Birth Defects Res. B Dev. Reprod. Toxicol. (2004) [Pubmed]
  5. Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits. Henry, S.P., Denny, K.H., Templin, M.V., Yu, R.Z., Levin, A.A. Birth Defects Res. B Dev. Reprod. Toxicol. (2004) [Pubmed]
  6. Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide. Henry, S.P., Monteith, D.K., Matson, J.E., Mathison, B.H., Loveday, K.S., Winegar, R.A., Matson, J.E., Lee, P.S., Riccio, E.S., Bakke, J.P., Levin, A.A. Mutagenesis (2002) [Pubmed]
  7. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Henry, S.P., Beattie, G., Yeh, G., Chappel, A., Giclas, P., Mortari, A., Jagels, M.A., Kornbrust, D.J., Levin, A.A. Int. Immunopharmacol. (2002) [Pubmed]
  8. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication. Henry, S.P., Miner, R.C., Drew, W.L., Fitchett, J., York-Defalco, C., Rapp, L.M., Levin, A.A. Invest. Ophthalmol. Vis. Sci. (2001) [Pubmed]
  9. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?. Henry, S.P., Geary, R.S., Yu, R., Levin, A.A. Curr. Opin. Investig. Drugs (2001) [Pubmed]
  10. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. Henry, S., Stecker, K., Brooks, D., Monteith, D., Conklin, B., Bennett, C.F. J. Pharmacol. Exp. Ther. (2000) [Pubmed]
  11. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Henry, S.P., Templin, M.V., Gillett, N., Rojko, J., Levin, A.A. Toxicol. Pathol (1999) [Pubmed]
  12. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Henry, S.P., Bolte, H., Auletta, C., Kornbrust, D.J. Toxicology (1997) [Pubmed]
  13. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Henry, S.P., Monteith, D., Levin, A.A. Anticancer Drug Des. (1997) [Pubmed]
  14. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Henry, S.P., Monteith, D., Bennett, F., Levin, A.A. Anticancer Drug Des. (1997) [Pubmed]
 
WikiGenes - Universities